- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
51 result(s) found for: Human genome.
Displaying page 1 of 3.
EudraCT Number: 2005-003041-14 | Sponsor Protocol Number: 565 | Start Date*: 2005-09-20 |
Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna | ||
Full Title: Anti-inflammatory effect of statins in the human endotoxin model | ||
Medical condition: Healthy volunteers are tested in an endotoxemia model | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004570-28 | Sponsor Protocol Number: HGS1006-C1121 | Start Date*: 2012-09-13 | |||||||||||
Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC) | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Acti... | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) CZ (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004961-14 | Sponsor Protocol Number: UV2013/4 | Start Date*: 2014-06-11 | |||||||||||
Sponsor Name:Kliniken Kärnan Urology Centre | |||||||||||||
Full Title: Pilot study to investigate the mode of action (MoA) of Uro-Vaxom® on a molecular level in pre-menopausal women suffering from recurrent urinary tract infections (rUTI) | |||||||||||||
Medical condition: Recurrent urinary tract infections (rUTI) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005672-42 | Sponsor Protocol Number: HGS1006-C1112 | Start Date*: 2013-06-11 | |||||||||||
Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC) | |||||||||||||
Full Title: A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus... | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007276-41 | Sponsor Protocol Number: Ram_GEP_1 | Start Date*: 2008-05-13 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | ||
Full Title: Gene expression profiling in skeletal muscle of healthy subjects treated with ramipril | ||
Medical condition: healthy young males | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003814-18 | Sponsor Protocol Number: HGS1006-C1115 | Start Date*: 2012-05-03 | |||||||||||
Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC) | |||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys... | |||||||||||||
Medical condition: Systemic lupus erythematosis (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) AT (Completed) CZ (Completed) SE (Completed) BE (Completed) PT (Completed) ES (Completed) DK (Completed) GB (Completed) BG (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003407-15 | Sponsor Protocol Number: SRP-9001-104 | Start Date*: 2023-08-08 |
Sponsor Name:Sarepta Therapeutics, Inc | ||
Full Title: An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of SRP-9001 in association with imlifidase in Subjects with Duchenne Muscular Dystrophy with pre-exis... | ||
Medical condition: Duchenne muscular dystrophy | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male | |
Trial protocol: ES (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005113-21 | Sponsor Protocol Number: RDEA806-202 | Start Date*: 2008-11-20 | |||||||||||
Sponsor Name:Ardea Biosciences, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Phase 2b Trial to Determine The Efficacy, Tolerability And Safety Of 3 Dose Regimens Of RDEA806 and Open-Label Efavirenz as Active Control in HIV 1-Infected... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003689-41 | Sponsor Protocol Number: CRAD001YGB11 | Start Date*: 2012-11-19 |
Sponsor Name:Novartis Pharmaceuticals UK Ltd | ||
Full Title: A Phase IV multicentre, open label study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with e... | ||
Medical condition: oestrogen receptor positive breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003429-32 | Sponsor Protocol Number: ImbruVeRCHOP-Trial | Start Date*: 2017-02-09 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: “Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2” | ||
Medical condition: untreated CD20-positive DLBCL-like aggressive Non-Hodgkin’s lymphoma, 61-80 years of age with unfavorable risk profile (IPI ≥ 2) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004569-33 | Sponsor Protocol Number: HGS1006-C1100 | Start Date*: 2012-12-20 | ||||||||||||||||
Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC) | ||||||||||||||||||
Full Title: A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission ... | ||||||||||||||||||
Medical condition: Wegener’s granulomatosis (WG) Microscopic polyangiitis (MPA) Vasculitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) BE (Completed) ES (Completed) IE (Completed) SE (Completed) HU (Completed) IT (Prematurely Ended) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-007648-85 | Sponsor Protocol Number: HGS1006-C1074 | Start Date*: 2009-02-06 | |||||||||||
Sponsor Name:Human Genome Sciences, Inc. | |||||||||||||
Full Title: A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 ... | |||||||||||||
Medical condition: Systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) NL (Completed) BE (Completed) GB (Completed) CZ (Completed) ES (Completed) IT (Completed) SE (Completed) SK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000867-24 | Sponsor Protocol Number: ALFR-HC-04 | Start Date*: 2005-05-23 |
Sponsor Name:Human Genome Sciences, Inc. | ||
Full Title: A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION... | ||
Medical condition: Hepatitis type C chronic | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-001542-29 | Sponsor Protocol Number: 106260 | Start Date*: 2015-06-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIb, randomized, double-blind, placebo-controlled study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family. | ||
Medical condition: Rotavirus (RV) gastroenteritis | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-005080-40 | Sponsor Protocol Number: FLT180a-04 | Start Date*: 2018-05-15 | |||||||||||
Sponsor Name:Freeline Therapeutics Limited | |||||||||||||
Full Title: An Open-Label, Multicentre, Long-Term Follow-Up Study to Investigate the Safety and Durability of Response Following Dosing of a Novel Adeno-Associated Viral Vector (FLT180a) in Patients with Haemo... | |||||||||||||
Medical condition: Haemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000298-11 | Sponsor Protocol Number: ISS22810078 | Start Date*: 2015-09-02 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA "ISTITUTI OSPITALIERI" DI CREMONA | |||||||||||||
Full Title: A phase II, open label, controlled study of olaparib in locally advanced ER, PgR and HER2 negative (Triple Negative) and in locally advanced germline BRCA mutation-positive breast cancer patients: ... | |||||||||||||
Medical condition: Locally advanced breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021821-10 | Sponsor Protocol Number: MSC_Apceth_001 | Start Date*: 2011-01-21 | |||||||||||
Sponsor Name:apceth GmbH & Co. KG | |||||||||||||
Full Title: Open, Randomized, Mono-centre, Two-Parallel Group Clinical Phase I/II Trial on the Evaluation of Tolerability and Efficacy of an Intravenous In-fusion of Human Bone-Marrow Derived Autologous, CD34-... | |||||||||||||
Medical condition: Critical Limb Ischemia in Patients with Advanced Peripheral Arterial Occlusive Disease Subsequent to Percutaneous Transluminal Angioplasty | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004271-22 | Sponsor Protocol Number: INSIGHTPROTOCOL006 | Start Date*: 2015-02-25 | |||||||||||
Sponsor Name:Regents of the University of Minnesota | |||||||||||||
Full Title: Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG) | |||||||||||||
Medical condition: Infleunza | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DK (Completed) ES (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020798-17 | Sponsor Protocol Number: HGS1012-C1103 | Start Date*: 2011-07-01 | |||||||||||
Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC) | |||||||||||||
Full Title: A Randomized, Multi-Center, Blinded, Placebo-Controlled Study of Mapatumumab ([HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination with Sorafenib as a First-Line Therapy in Subj... | |||||||||||||
Medical condition: Advanced Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001714-96 | Sponsor Protocol Number: R2222-RSV-1332 | Start Date*: 2015-11-03 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in ... | |||||||||||||
Medical condition: Medically attended respiratory syncytial virus infection | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) HU (Completed) FI (Completed) BG (Completed) ES (Completed) CZ (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
